{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:40:38Z","timestamp":1777891238694,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Subst\ufffdAbuse"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:p>\n                    In a recent article, Lund et al sought to compare maternal and neonatal outcomes of various treatment regimens for opioid dependence during pregnancy.\n                    <jats:sup>1<\/jats:sup>\n                    In their background, discussion the authors state that \u201cIn the United States buprenorphine plus naloxone [Suboxone\u00ae] \u2026 has been the preferred form of prescribed buprenorphine due to its reduced abuse liability relative to buprenorphine alone [Subutex\u00ae].\u201d This claim is certainly consistent with the view of the firm that has manufactured and sold both products, Reckitt Benckiser. In September of 2011, the company announced that it was \u201c\u2026 discontinuing distribution and sale of Subutex\u00ae tablets as we believe that mono product (product containing buprenorphine alone with no naloxone) creates a greater risk of misuse, abuse and diversion \u2026\u201d.\n                    <jats:sup>2<\/jats:sup>\n                    Supporting evidence for the alleged \u201creduced abuse liability\u201d appears to be lacking, however, and evidence cannot be located in the two references cited by Dr. Lund and his co-authors, which in fact are silent on the subject of abuse potential.\n                    <jats:sup>3 , 4<\/jats:sup>\n                    In contrast, it has been reported that the transition to buprenorphine\/naloxone from the mono formulation has been associated with \u201c\u2026 no reduction in injection risk behaviors among IDUs.\u201d\n                    <jats:sup>5<\/jats:sup>\n                  <\/jats:p>","DOI":"10.4137\/sart.s12250","type":"journal-article","created":{"date-parts":[[2013,5,26]],"date-time":"2013-05-26T17:12:18Z","timestamp":1369588338000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on \u201cA Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes\u201d"],"prefix":"10.4137","volume":"7","author":[{"given":"Robert G.","family":"Newman","sequence":"first","affiliation":[{"name":"Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, 555 W. 57th St., NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan G.","family":"Gevertz","sequence":"additional","affiliation":[{"name":"Independent Healthcare Consultant, Scarsdale, NY and Westchester County Health Care Corporation, Valhalla, NY, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,5,26]]},"reference":[{"key":"bibr1-SART.S12250","first-page":"61","volume":"7","author":"Lund I.O.","year":"2013","journal-title":"Subst Abuse."},{"key":"bibr2-SART.S12250","unstructured":"Discontinuation of sale and distribution of Subutex\u00ae tablets CIII. Reckitt Benckiser. http:\/\/buprenorphine.samhsa.gov\/SubutexDiscontinuation9-16-11.pdf. Updated Sep 16, 2011. Accessed Apr 22, 2013."},{"key":"bibr3-SART.S12250","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022164"},{"key":"bibr4-SART.S12250","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.352"},{"key":"bibr5-SART.S12250","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711104010028"},{"key":"bibr6-SART.S12250","unstructured":"Opioid agonist\/antagonists for opioid dependence. Good Rx. http:\/\/www.goodrx.com\/opioid-dependence\/opioid-agonist-antagonists. Accessed Apr 22, 2013."},{"key":"bibr7-SART.S12250","unstructured":"Reckitt's Suboxone strategy is really about patients or profits? Forbes. http:\/\/www.forbes.com\/sites\/edsilverman\/2012\/10\/12\/reckitts-suboxone-strategy-is-really-about-patients-or-profits\/. Accessed Apr 22, 2013."}],"container-title":["Substance Abuse: Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/SART.S12250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4137\/SART.S12250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/SART.S12250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:57:53Z","timestamp":1777615073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4137\/SART.S12250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":7,"alternative-id":["10.4137\/SART.S12250"],"URL":"https:\/\/doi.org\/10.4137\/sart.s12250","relation":{},"ISSN":["1178-2218","1178-2218"],"issn-type":[{"value":"1178-2218","type":"print"},{"value":"1178-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"article-number":"SART.S12250"}}